CYLD (Cylindromatosis Lysine Specific Deubiquitinase) is a unique tumor suppressor deubiquitinase that specifically cleaves Lys63-linked and linear polyubiquitin chains from substrate proteins. Originally identified as the gene mutated in familial cylindromatosis, CYLD has emerged as a critical regulator of multiple signaling pathways with profound implications for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). [1]
| CYLD Protein | |
|---|---|
| Protein Name | Cylindromatosis Lysine Specific Deubiquitinase |
| Gene Symbol | [CYLD](/genes/cyld) |
| UniProt ID | [Q9UWB3](https://www.uniprot.org/uniprot/Q9UWB3) |
| Molecular Weight | 93 kDa (956 amino acids) |
| Protein Class | Ubiquitin-specific protease (USP), Tumor suppressor |
| Tissue Expression | Ubiquitous, high in brain, testis, pancreas |
| Subcellular Location | Cytoplasm, nucleus, cell membranes |
| Associated Diseases | [Alzheimer's](/diseases/alzheimer-disease), [Parkinson's](/diseases/parkinson-disease), [ALS](/diseases/als), cylindromatosis |
CYLD is a member of the ubiquitin-specific protease (USP) family that specifically removes Lys63-linked polyubiquitin chains and linear polyubiquitin chains from substrate proteins. Unlike many USPs, CYLD demonstrates remarkable substrate specificity, primarily targeting Lys63-linked polyubiquitin modifications that serve as signaling platforms rather than degradation signals. [2]
The catalytic mechanism involves:
The CYLD protein contains:
CYLD is a master negative regulator of NF-κB signaling, one of the most important pro-inflammatory pathways in the brain. Under baseline conditions, CYLD constitutively removes Lys63-linked ubiquitin chains from key NF-κB signaling components including:
During neuroinflammation, loss of CYLD function leads to hyperactivation of NF-κB, resulting in increased production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 by microglia and astrocytes. This creates a feed-forward loop of neuroinflammation that drives disease progression in both AD and PD. [3]
CYLD also modulates MAPK/ERK signaling, which is critically involved in neuronal survival and synaptic plasticity. Dysregulation of this pathway contributes to:
Recent studies indicate CYLD interacts with β-catenin degradation complexes, influencing Wnt signaling pathways that play important roles in neural development and adult neurogenesis.
In Alzheimer's disease, CYLD expression is significantly reduced in brain tissue from AD patients compared to age-matched controls. This reduction correlates with increased NF-κB activity and elevated pro-inflammatory cytokine expression. CYLD deficiency in microglia leads to:
[4] demonstrated that CYLD knockout mice show worsened cognitive deficits and accelerated amyloid pathology, establishing CYLD as a protective factor in AD. [5]
CYLD plays a direct role in tau pathogenesis through multiple mechanisms:
[6] demonstrated CYLD is a novel tau interaction partner, with decreased CYLD-tau association in AD brains correlating with increased tau pathology. [7]
CYLD influences amyloid precursor protein (APP) processing indirectly through NF-κB-mediated effects on β-secretase (BACE1) expression. Reduced CYLD leads to increased BACE1 transcription and elevated Aβ production.
[8] established that CYLD is essential for dopaminergic neuron survival in the substantia nigra. CYLD deficiency leads to:
The protective mechanism involves NF-κB-mediated regulation of anti-apoptotic genes including Bcl-2 and XIAP.
CYLD interacts with alpha-synuclein aggregation pathways:
[9] showed CYLD overexpression protects against alpha-synuclein toxicity in cellular and mouse models of PD, while CYLD knockdown exacerbates pathology.
In Parkinson's disease, mitochondrial dysfunction is a central pathogenic mechanism. [10] demonstrated CYLD regulates mitochondrial quality control through:
[11] showed CYLD deficiency impairs mitophagy, leading to accumulation of dysfunctional mitochondria in dopaminergic neurons.
As in Alzheimer's disease, CYLD deficiency in PD models leads to:
In ALS, CYLD is implicated through its roles in:
CYLD is a critical regulator of autophagy, a key cellular pathway for clearing damaged proteins and organelles:
Dysregulation of CYLD-dependent autophagy contributes to accumulation of protein aggregates in all major neurodegenerative diseases.
[12] demonstrated CYLD plays important roles in synaptic function:
The protective functions of CYLD in neurodegeneration make it an attractive therapeutic target:
CYLD expression levels in cerebrospinal fluid (CSF) and blood may serve as:
The CYLD gene (Cylindromatosis Lysine Specific Deubiquitinase) is located on chromosome 16q12.1 and spans approximately 37 kb of genomic DNA. The gene consists of 20 exons encoding a 956-amino acid protein. Multiple transcript variants have been identified, with the major isoform (NM_015247) encoding the full-length deubiquitinase.
Key structural features of the CYLD gene include:
The CYLD protein exhibits a distinctive multi-domain architecture:
N-terminal region (1-300 aa)
Central region (300-700 aa)
C-terminal catalytic domain (700-956 aa)
CYLD activity and localization are regulated by multiple post-translational modifications:
Phosphorylation: Multiple serine/threonine phosphorylation sites
Ubiquitination: CYLD itself is ubiquitinated
Sumoylation: SUMO conjugation at multiple lysine residues
Acetylation: Acetylation of the catalytic cysteine regulates activity
CYLD belongs to the USP family but has unique structural features:
| Feature | CYLD | USP7 | USP15 | USP28 |
|---|---|---|---|---|
| Catalytic domain | C-terminal | C-terminal | C-terminal | C-terminal |
| N-terminal domains | CAP-Gly, B Box | None | DUSP | DUSP |
| Substrate specificity | Lys63, linear | Ubiquitin, histone | K48, K63 | K48 |
| Regulatory mechanisms | Phosphorylation | Auto-inhibition | Phosphorylation | Phosphorylation |
CYLD demonstrates remarkable substrate specificity compared to other DUBs:
Lys63-linked polyubiquitin chains
Linear polyubiquitin chains
Mixed-linkage chains
The substrate recognition mechanism involves:
CYLD associates with multiple signaling complexes:
In the cerebral cortex, CYLD plays critical roles in:
The hippocampus shows high CYLD expression:
In the substantia nigra pars compacta:
CYLD in cerebellar Purkinje cells:
Several CYLD knockout mouse models have been generated:
Global CYLD KO
Conditional CNS KO
Microglia-specific KO
| Model | Phenotype | Relevance |
|---|---|---|
| Global KO | Chronic inflammation,皮肤腺瘤 | Cylindromatosis |
| Neuron KO | Memory deficits, LTP impairment | AD/PD |
| Microglia KO | Enhanced neuroinflammation | All NDs |
| Double KO (with tau) | Accelerated tauopathy | AD |
CYLD modulates the amyloid cascade through:
APP processing regulation
Aβ clearance enhancement
Neurotoxicity reduction
CYLD-tau interactions represent a novel therapeutic target:
Direct protein-protein interaction
Indirect mechanisms
CYLD regulates α-synuclein handling through multiple pathways:
Autophagy regulation
Proteasomal degradation
Aggregate prevention
CYLD is essential for mitochondrial health:
Mitophagy initiation
Mitochondrial dynamics
Bioenergetic function
CYLD is implicated in ALS through:
TDP-43 ubiquitination
Axonal transport
CYLD as a therapeutic target:
Protective functions validated
Safety considerations
Small molecule activators
Protein-protein interaction disruptors
NF-κB inhibitors
Autophagy enhancers
Gene therapy approaches
Kovalenko A et al. The tumor suppressor CYLD acts as an NF-κB negative regulator. Mol Cell. 2003. ↩︎
Zhang M et al. Structural basis for the Lysine-specific deubiquitinase function of CYLD. Mol Cell. 2015. ↩︎
Lim JH et al. CYLD regulates neuroinflammation through NF-κB signaling in microglia. J Neuroinflammation. 2020. ↩︎
Tang B et al. CYLD deficiency exacerbates neuroinflammation in a mouse model of AD. J Neurosci. 2022. ↩︎
Massoumi R et al. CYLD - a tumor suppressor with versatile functions in cell signaling. Trends Cell Biol. 2011. ↩︎
Nikopoulos K et al. CYLD in tauopathy: deubiquitinase regulates tau pathology. Acta Neuropathol Commun. 2019. ↩︎
Zhao L et al. The role of CYLD in protein aggregation and degradation. Cell Mol Neurobiol. 2021. ↩︎
Zhang J et al. CYLD deficiency enhances dopaminergic neuron degeneration in Parkinson's disease. Mov Disord. 2016. ↩︎
Wang Y et al. CYLD protects against alpha-synuclein toxicity in Parkinson's models. Nat Commun. 2020. ↩︎
Liu X et al. CYLD modulates mitochondrial function in dopaminergic neurons. Cell Death Dis. 2021. ↩︎
Park J et al. CYLD regulates mitophagy in Parkinson's disease. Autophagy. 2022. ↩︎
Hu X et al. CYLD-mediated deubiquitination in synaptic function. Front Mol Neurosci. 2023. ↩︎